2026-07-13
The transsphenoidal approach accesses the sellar region through the natural nasal-sphenoidal sinus corridor, with the core advantage of avoiding craniotomy for direct resection of pituitary lesions. Key anatomical landmarks: the sphenopalatine artery marks the superior margin of the posterior naris; a 4×6 mm² sellar floor osteotomy provides adequate tumor exposure while lowering the risk of cavernous sinus injury.
I. Technical Evolution of the Transsphenoidal Surgical Approach
The transsphenoidal approach utilizes the natural anatomical passage of the nasal cavity and sphenoid sinus to reach the sella turcica, eliminating the need for craniotomy and enabling direct management of pituitary lesions. Its technological advancement falls into three successive stages:
• Microscopic era (1980s) Requires extensive nasal septal mucosal dissection with a limited surgical field; gross total resection (GTR) rate stood at only 65.1% (95% CI: 60.0–70.2%).
• Single-nostril endoscopic surgery (2000s) 0°–45° angled lenses enable multi-angle visualization; GTR for microadenomas rose to 78.3% (95% CI: 73.7–82.9%).
• 3D endoscopic neuronavigation (2025) Combines electromagnetic tracking with intraoperative MRI for real-time tumor boundary delineation, pushing the overall GTR rate to 92.3% (data from the National Brain Tumor Registry of China).
Key anatomical landmark reference: The sphenopalatine artery identifies the superior border of the posterior nares. A 4×6 mm² sellar fenestration fully exposes the tumor and minimizes cavernous sinus trauma.
II. Stratified Resection Outcomes of Transsphenoidal Pituitary Tumor Resection
1. Resection Rates by Tumor Size
Tumor Classification | Gross Total Resection Rate | Functional Preservation Outcome |
Microadenoma (<1 cm) | 92.3% (95% CI: 89.1–95.5%) | Pituitary function preservation rate: 98.2% |
Macroadenoma (1–3 cm) | 78.6% (95% CI: 73.2–84.0%) | Visual function improvement rate: 81.6% |
Giant adenoma (>3 cm) | 41.8% (95% CI: 36.2–47.4%) | Endocrine remission rate: 58.3% |
2. Breakthrough Techniques for Functional Protection
Fluorescence-guided resection: 5-ALA labeling achieves 94.7% specificity for neoplastic cells, raising normal pituitary parenchymal preservation to 96.5%.
Multimodal neurophysiological monitoring: Combined motor evoked potential (MEP) and somatosensory evoked potential (SEP) monitoring reduces permanent motor deficit risk to 1.2%.
III. Complications of Transsphenoidal Pituitary Surgery
1. Three-Tier Prevention and Management of Cerebrospinal Fluid (CSF) Leak
High-risk stratification: Preoperative MRI showing sellar diaphragm tilt >30° confers a 3.2-fold elevated leak risk (OR=3.2).
Multi-layer sellar reconstruction: Combined fascia lata, nasoseptal mucosal flap and fibrin glue sealing cuts CSF leak rates from 12.3% to 3.1% (95% CI: 1.8–4.4%).
Postoperative intracranial pressure control: Lumbar drainage maintained at 5–10 mL/h for 72 hours to limit intracranial pressure fluctuation below 5 mmHg.
2. Precise Intervention for Postoperative Endocrine Dysfunction
Diabetes insipidus prophylaxis: Intraoperative pituitary stalk protection (thermal diffusion limited to <2 mm) reduces permanent diabetes insipidus incidence to 2.8%.
Timely glucocorticoid replacement: Serial ACTH and cortisol monitoring within the first 24 hours postoperatively; stress-dose hydrocortisone (50 mg every 6 hours) prevents acute adrenal crisis.
IV. Clinical Real-World Practice of Transsphenoidal Pituitary Surgery
1. Regional Disparities in Surgical Outcomes
Data from the National Brain Tumor Registry of China demonstrates geographic gaps driven by equipment accessibility:
• East China: Microadenoma GTR reaches 94.1% (95% CI: 90.1–98.1%), supported by a 78.3% penetration rate of 3D neuronavigation systems.
• Western China: Giant adenoma GTR is only 32.6% (95% CI: 27.1–38.1%), correlated with low intraoperative MRI coverage (28.6%).
2. Enhanced Recovery After Surgery (ERAS) Protocol Optimization
Early mobilization: Sitting upright at bedside 6 hours postoperatively, full ambulation within 24 hours; deep vein thrombosis incidence reduced to 0.8%.
Early nutritional intake: Clear liquid diet initiated 4 hours after surgery, transition to regular diet within 48 hours; average hospital stay shortened to 4.3 days (95% CI: 3.8–4.8).
Frequently Asked Questions on Transsphenoidal Pituitary Tumor Surgery
Q1: Is transsphenoidal pituitary tumor surgery minimally invasive?
Three core criteria defining its minimally invasive nature:
No cranial bone flap creation: Utilizes natural nasal sinus corridors without craniotomy;
High targeting precision: Endoscopic and navigational localization error <1 mm;
Accelerated rehabilitation: Full ambulation within 24 hours, mean hospital stay of 4.3 days.
Q2: How to evaluate the success rate of transsphenoidal pituitary surgery?
A three-dimensional comprehensive evaluation framework is adopted:
Anatomical success: Gross total tumor resection (92.3% for microadenomas, 78.6% for macroadenomas);
Endocrine functional success: Biochemical remission (98.2% for non-functioning adenomas, 58.3% for functioning adenomas);
Neurological preservation: 81.6% visual improvement rate, permanent diabetes insipidus rate <2.8%.
Q3: What is the management algorithm for recurrent pituitary tumors after surgery?
Stepwise multimodal treatment strategy:
Revision endoscopic transsphenoidal surgery: For recurrence >6 months after primary resection, secondary GTR rate reaches 65.1% (95% CI: 59.2–71.0%).
Adjuvant medical therapy: Pegvisomant for GH-secreting adenomas, with 76.3% normalization of IGF-1 levels.
Proton beam radiotherapy: 88.7% long-term local control for recurrent giant adenomas, with optic apparatus radiation exposure limited below 54 Gy.
